comparemela.com
Home
Live Updates
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023 : comparemela.com
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023
PDUFA target action date set to occur by December 8, 2023
NEW YORK, June 6, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for... | June 6, 2023
Related Keywords
California
,
United States
,
John Mullaly
,
Lisa Guiterman
,
Stacy Lindborg
,
Chaim Lebovits
,
Drug Administration
,
California Institute For Regenerative Medicine
,
Advisory Committee
,
Lifesci Advisors
,
Central Nervous System Drugs Advisory Committee
,
European Medicines Agency
,
National Ms Society
,
Brainstorm Cell Therapeutics Inc
,
Nasdaq
,
Brainstorm Cell Therapeutics
,
Biologics License Application
,
Prescription Drug User Fee Act
,
Brainstorm President
,
Nurown Phase
,
Rating Scale
,
Floor Effect
,
Storm Cell Therapeutics
,
Orphan Drug
,
California Institute
,
Regenerative Medicine
,
Harbor Statement
,
Sci Advisors
,
Brainstorm Cell Therapeutics Inc Stock Exchange
,
News
,
Information
,
Press Release
,
Pdufa
,
Target
,
Action
,
Gate
,
Pet
,
O
,
Ccur
,
Y
,
December
,
Pune
,
023
,
Fell
,
Herapeutics
,
Reading
,
Developer
,
F
,
Adult
,
Item
,
Herapeutics Bcli Us10501e2019
,
comparemela.com © 2020. All Rights Reserved.